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The Authors Reply: We thank Dr Angelotti et al.1 for their
comments regarding our paper deﬁning the ontogeny of CD24
in the human kidney,2 and for their suggestions for the use of
anti-CD133 monoclonal antibodies to the CD133/1 and
CD133/2 epitopes for the selection and puriﬁcation of renal
progenitor cells. We would like to emphasize that the purpose
of our report was to deﬁne, using high quality immunohisto-
chemical analyses of human fetal kidneys, the precise spatial
and temporal localization of CD24, so as to suggest potential
roles of this cell-surface antigen in normal and abnormal
human kidney development.
We of course defer to views of Dr Angelotti et al. regarding
the best technique of isolation of kidney progenitor cells, but
we would disagree with their interpretation of our results on
CD133 expression. In fact, although CD133 expression using
our polyclonal antibody was less restricted than theirs, we did
in fact show co-localization of CD133 and CD24 in early
developing nephron epithelial structures, which, given post-
natal CD133 (or prominin) expression, not surprisingly
express this antigen.
Finally, although the CD133/1 and CD133/2 epitopes may
be more speciﬁc to renal progenitors, we suspect that some of
the differences seen in our work and theirs, may have more to
do with immunohistochemistry technique, sample collection,
and tissue ﬁxation, on the basis of the details of their included
photomicrographs.
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Paraproteinemia-associated
pseudohypercreatininemia across
different analytical methodologies
To the Editor: The case reported by Rudofsky et al.1
illustrated that clinicians and laboratorians need to be
cautious of potential analytical interference secondary to
paraproteinemia. Recently, we encountered an 81-year-old
man with history of IgM k myeloma and elevated creatinine
concentration of 6.5mg/dl (normal: 0.7–1.2mg/dl), deter-
mined using the modiﬁed Jaffe´ method by Roche (Mannheim,
Germany) DP Modular Analytics analyzer. Considering
patient’s poor premorbid status, conservative and supportive
management of renal failure was decided.
The discrepant urea to creatinine ratio and all along normal
potassium concentrations were noticed by the chemical
pathologist. Distorted reaction curve was noted upon data
retrieval. Serial dilution of patient specimen with quality control
material showed the creatinine concentration was only 2.1mg/
dl. Creatinine level was measured as 1.7mg/dl by enzymatic
method with J&J Vitros (Raritan, NJ, USA) dry chemistry ana-
lyzer. Serum cystatin C was 1.17mg/l (normal: 0.50–1.00mg/l).
Physicians were contacted and ﬁndings explained.
Paraproteins interfering with Jaffe´ method for creatinine
determination have been reported.2 Analyses of numerous
clinically important analytes and electrolytes can be interfered
by paraproteins in an extremely unpredictable manner,
affecting different methodologies of automated assays. There
is poor correlation between the subtype and level of
paraproteins and the likelihood of in vitro interference.3
Enhanced clinical alertness helps picking up false results and
prevents patient damages, including anxiety and medication
underdosing. From the laboratory’s perspective, proper
procedures in handling specimens with paraproteins should
be in place and appropriately documented. Platforms with
alternative methodologies should be readily accessible in
processing doubtful cases. Interpretation and authorization of
abnormal results by chemical pathologists can further
minimize reporting misleading results directly from auto-
mated analyzers. Finally, the importance of effective commu-
nications between physicians and chemical pathologists
cannot be overemphasized.
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The Authors Reply: Short time after our report of a patient
with pseudohypercreatininemia due to Waldenstro¨m’s macro-
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